Media Library

A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, deliberate on results from recent clinical trials showing the improvement in progression-free survival after first-line maintenance therapy with PARP inhibitors in patients with ovarian cancer, regardless of HRD status. The experts consider the impact of these data on providing improved treatment options for these patients. View Video ›

Changes in HRD “Fingerprints” in Patients with Ovarian Cancer and Their Impact on Clinical Outcomes
Amina Ahmed, MD, and Paula Anastasia, RN, MN, AOCN, debate the need for rebiopsy and retesting of molecular biomarkers in patients with HRD-discordant responses. The experts agree that reliability of the HRD “fingerprint” is dependent on the validity of the HRD test used as well as the ability to interpret results from these tests. View Video ›

The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer
Ali McBride, PharmD, and Paula Anastasia, RN, MN, AOCN, discuss how results from germline and somatic HRD testing help provide new options for patients with ovarian cancer. This approach has been a “game changer” in clinical outcomes for these patients. View Video ›

The Role of Genetic Testing in Patients with Ovarian Cancer
Amina Ahmed, MD, MS, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, MS, discuss the importance of genetic testing in the workup of patients with ovarian cancer, including both germline and somatic testing. The experts consider practice guidelines and results of recent clinical trials and their perspectives on the impact of genetic testing on treatment as well as clinical outcomes. View Video ›

What is Minimal Residual Disease (MRD) Negativity?
Leslie Lauersdorf breaks down what it means to be MRD negative and how she explains MRD negativity to her patients. View Video ›

Multiple Myeloma as a Chronic Disease
As multiple myeloma moves toward being considered a chronic disease, nurses and navigators have new considerations to keep in mind when treating their patients. View Video ›

Triplets versus Quads
Leslie Lauersdorf explains triplet versus quad regimens in relation to multiple myeloma. View Video ›

CAR T-Cell Data in Multiple Myeloma
Leslie Lauersdorf discusses key considerations for nurses and navigators surrounding the use of CAR T-cell therapy in multiple myeloma. View Video ›

Latest Developments in Multiple Myeloma
Leslie Lauersdorf provides an overview of some of the most exciting clinical developments in multiple myeloma based on data presented at ASH 2019. View Video ›

Working Together to Find the New Standard of Care
Dr Andrey Antov values the benefits of working within an interdisciplinary team to advance cancer care and help patients. View Video ›

Page 6 of 12

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: